• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Ipilimumab plus anti-PD-1 therapy is effective in patients with anti-PD-L1 resistant metastatic melanoma

byTeddy Guo
July 7, 2021
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

Click to read the study in The Lancet Oncology.

RELATED REPORTS

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

Ivonescimab improves survival in advanced non-small cell lung cancer

BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma

Tags: advanced melanomaanti-PD-1anti-PD-L1anti-PD-L1 resistant melanomaAtezolizumabBRAF-mutated melanomacutaneous melanomadermatologyipilimumabmalignant melanomamelanomamelanoma survivalmetastatic melanomaNivolumabPembrolizumabprimary cutaneous melanomaskin cancer
Previous Post

Rituximab increases sustained complete remission in patients with pemphigus vulgaris

 Next Post

Standard cytisine treatment for smoking cessation does not demonstrate noninferiority compared to standard varenicline treatment

RelatedReports

Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified
AI Roundup

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

June 12, 2025
Lessons from real-world implementation of lung cancer screening
Chronic Disease

Ivonescimab improves survival in advanced non-small cell lung cancer

April 30, 2025
Significant reduction in prostate screening rates after revised guidelines
Chronic Disease

BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma

April 28, 2025
Development of a risk index for colorectal cancer screening
Chronic Disease

Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer

April 3, 2025
Next Post
Strict tobacco licensing laws linked to reduced adolescent smoking initiation

Standard cytisine treatment for smoking cessation does not demonstrate noninferiority compared to standard varenicline treatment

Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis

Clopidogrel monotherapy is superior to aspirin monotherapy for chronic maintenance after percutaneous coronary intervention

Combined MRI and NIH stroke scores may predict stroke prognosis

Patients with moderate-severe traumatic brain injury may achieve favourable functional outcomes within 12 months of recovery

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.